Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Citi
US Army
Cerilliant
Baxter
Novartis
Farmers Insurance
QuintilesIMS
Fuji

Generated: October 16, 2017

DrugPatentWatch Database Preview

Iroko Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for IROKO PHARMS LLC, and what generic alternatives to IROKO PHARMS LLC drugs are available?

IROKO PHARMS LLC has four approved drugs.

There are twelve US patents protecting IROKO PHARMS LLC drugs on IROKO PHARMS LLC drugs in the past three years.

There are eighty-seven patent family members on IROKO PHARMS LLC drugs in twenty-four countries.

Summary for Applicant: Iroko Pharms Llc

International Patents:87
US Patents:12
Tradenames:4
Ingredients:3
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Iroko Pharms Llc
ZORVOLEX
diclofenac
CAPSULE;ORAL204592-002Oct 18, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Iroko Pharms Llc
TIVORBEX
indomethacin
CAPSULE;ORAL204768-002Feb 24, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Iroko Pharms Llc
ZORVOLEX
diclofenac
CAPSULE;ORAL204592-002Oct 18, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Iroko Pharms Llc
ZORVOLEX
diclofenac
CAPSULE;ORAL204592-002Oct 18, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-002Oct 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-001Oct 22, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Iroko Pharms Llc
VIVLODEX
meloxicam
CAPSULE;ORAL207233-002Oct 22, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Iroko Pharms Llc
ZORVOLEX
diclofenac
CAPSULE;ORAL204592-001Oct 18, 2013RXYesNo► Subscribe► Subscribe ► Subscribe
Iroko Pharms Llc
ZORVOLEX
diclofenac
CAPSULE;ORAL204592-001Oct 18, 2013RXYesNo► Subscribe► SubscribeY ► Subscribe
Iroko Pharms Llc
TIVORBEX
indomethacin
CAPSULE;ORAL204768-002Feb 24, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for IROKO PHARMS LLC drugs

Drugname Dosage Strength Tradename Submissiondate
meloxicam
Capsules5 mg and 10 mg
VIVLODEX
1/9/2017
diclofenac sodium
Capsules18 mg and 35 mg
ZORVOLEX
6/6/2014

Non-Orange Book Patents for Iroko Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,735,450Formulation of diclofenac► Subscribe
9,522,135Formulation of indomethacin► Subscribe
9,095,496Formulation of indomethacin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Iroko Pharms Llc Drugs

Country Document Number Estimated Expiration
Japan2017019848► Subscribe
Morocco33296► Subscribe
Canada2951383► Subscribe
Japan6027890► Subscribe
Malaysia159208► Subscribe
Israel248699► Subscribe
South Korea20170002683► Subscribe
World Intellectual Property Organization (WIPO)2010121327► Subscribe
South Africa201108646► Subscribe
Mexico347290► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
Johnson and Johnson
Medtronic
QuintilesIMS
Federal Trade Commission
Merck
Express Scripts
Colorcon
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot